Amplia Therapeutics (ASX:ATX) has delivered an update on its clinical progress, announcing an additional confirmed partial tumour response in its ACCENT trial and presenting new data to investors that reinforce the potential of its FAK inhibitor narmafotinib in metastatic pancreatic cancer. …
Amplia reports new rumour response for narmafotinib in pancreatic cancer
December 14, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
The 'Dispatched' Podcast - Episode 1, Series 5
January 23, 2026 - - Podcast -
AusBiotech announces new advisory groups to support the life sciences sector
January 22, 2026 - - Latest News -
Specialised Therapeutics brings new hope to women with HER2-positive breast cancer in Thailand
January 22, 2026 - - Latest News -
New funding deal brings next-generation cystic fibrosis treatments closer for New Zealanders
January 22, 2026 - - Latest News -
For almost all of the last 40 years, Governments have aimed to make medicines less affordable, for everyone but them
January 22, 2026 - - Latest News -
argenx deepens Australian research footprint with Monash partnership
January 21, 2026 - - Latest News -
New data reinforce promise of cancer vaccine, with Australia playing a key role
January 21, 2026 - - Latest News